i3 announces next phase of strategic global expansion

11-Dec-2006

Pharmaceutical services company i3 announced the next phase of its global expansion, which includes organic and acquired growth in India, Latin America, and Eastern and Western Europe. Coupled with important acquisitions earlier this year in Canada and Asia/Pacific, these additions to the i3 family shall help i3's pharmaceutical clients bring high-quality, well-tested drugs to market faster and more affordably by augmenting i3's ability to provide customers access to a large pool of patients and investigators and the most efficient services from across the globe.

i3 announced its acquisition of one of Latin America's largest privately held contract research organizations (CRO), with operations in Argentina, Brazil, Costa Rica, Mexico, Peru and Uruguay. This full service CRO specializes in clinical research and professional outsourcing and has a wide range of medium to large pharmaceutical and biotechnology clients. i3 intends to operate the new organization as i3 Latin America.

i3 also is expanding into India with a full-service office in Delhi. In India, i3 will provide clinical research and data services offerings for India-specific and global trials. In addition to project management, monitoring, regulatory and quality assurance services, its data services offerings will include data entry and programming, data management, biostatistics and statistical programming. A staffing solutions business will meet the temporary staffing needs of pharmaceutical companies in India and provide recruiting and training support for i3 operations in India.

https://www.chemeurope.com/en/news/60020/i3-announces-next-phase-of-strategic-global-expansion.html